Association of statin use with risk of depression and anxiety: A prospective large cohort study

Gen Hosp Psychiatry. 2024 Sep-Oct:90:108-115. doi: 10.1016/j.genhosppsych.2024.07.015. Epub 2024 Jul 31.

Abstract

Objectives: To examine associations between regular statin use and the incidence of depression and anxiety.

Methods: This cohort was based on UK Biobank participants without depression/anxiety recruited between 2006 and 2010. The self-reported regular statin use was collected at baseline. Depression and anxiety outcomes were assessed by diagnostic interviews (international classification of diseases codes) and nondiagnostic scales (mental well-being questionnaires). Cox proportional hazards models adjusted for a wide range of confounders were used to estimate associations of statins with incident depression/anxiety.

Results: Among 363,551 eligible participants, 55,838 reported regular statin use. During a 13-year follow-up, 14,765 cases of depression and 15,494 cases of anxiety were identified. Compared with non-statin users, statin use was associated with reduced risk of depression (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.81, 0.94) and anxiety (HR: 0.90, 95% CI: 0.84, 0.97). Effects of statins on depression were consistent in sensitivity analyses and may be less influenced by unmeasured confounders. However, results of online survey data showed that statin use might not be associated with incident anxiety (HR: 0.96, 95% CI: 0.85, 1.09).

Conclusion: Regular statin use was associated with a lower risk of depression. No clear associations between statin use and anxiety were found.

Keywords: Anxiety; Cohort study; Depression; Regular statin use.

MeSH terms

  • Adult
  • Aged
  • Anxiety* / epidemiology
  • Depression* / epidemiology
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / administration & dosage
  • Incidence
  • Male
  • Middle Aged
  • Prospective Studies
  • United Kingdom / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors